About

 A virus being attacked by antibodies generated by immunisation with a virus-like particle vaccine

Our Story

2A Pharma’s history starts in 2005 when John Nieland, then Head of Immunology at Medigene AG together with colleagues Markus Hörer and Hildegard Büning, discovered how to replace peptides on the surface of a modified adenovirus with sequences of interest, to induce and enhance a specific antibody response.

This meant that the modified adenovirus – also called adeno associated virus-like particle (AAVLP) could be delivered inside the body, looking like an actual virus, creating an immune response but without being pathogenic.

The nature of the AAVLP would activate both the bodies innate and adaptive immune responses, exploiting the efficacy of the individual’s own immune system.

These adeno-associated virus-like particles (AAVLP) inventions were patented in later years, however the potential was never commercialised, due to Medigene’s decision to focus on other projects, and John Nieland left the company to pursue other opportunities.

Board of Directors

Peter Lainevool, Chairman

CEO S.A.B. Corporate Finance
read more

John Nieland

read more

Preben Bruun-Nyzell

read more

Team Members

John Nieland

COO
read more

Preben Bruun-Nyzell

CEO
read more

Emma Huus

Laboratory Technician
read more

Nicole Overmars

Communications Manager
read more

Timeline

2020

Phase 1 Clinical Trial of the AAVLP-HPV project completed

2019

Dr. Jens Renstrup joined the Board of Directors

2019

First volunteer in Phase 1 Clinical Trial of novel HPV L2 vaccine

2018

2A Pharma in collaboration with partners from DTI & DNASense granted EUR 653.000 Eurostars funding for 2AP07

2018

2A Pharma raised USD 3M for 2AP07

2017

Preparation for Phase 1 Clinical Trial of 2AP01

2017

Peter Lainevool joined the Board of Directors

2016

2A Pharma AB founded

2016

2A Pharma inlicensed the AAVLP technology from Medigene

2016

2A Pharma closed its first financing round of SEK 27M, c. EURO 2.5M

2012

AAVLP inventions patented

2005

John Nieland, Markus Hörer and Hildegard Büning discovered how to replace peptides on the surface of a modified adenovirus with antigens (to induce and enhance a specific antibody response)

Career

2A Pharma is always on the lookout for talented people who can help us progress our vaccine R&D. If this is your passion and you think you have relevant experience, please contact us at info@2apharma.com